Repositioning Candidate Details
| Candidate ID: | R0008 |
| Source ID: | DB00122 |
| Source Type: | approved; nutraceutical |
| Compound Type: | small molecule |
| Compound Name: | Choline |
| Synonyms: | |
| Molecular Formula: | C5H14NO |
| SMILES: | C[N+](C)(C)CCO |
| Structure: |
|
| DrugBank Description: | A basic constituent of lecithin that is found in many plants and animal organs. It is important as a precursor of acetylcholine, as a methyl donor in various metabolic processes, and in lipid metabolism. |
| CAS Number: | 62-49-7 |
| Molecular Weight: | 104.1708 |
| DrugBank Indication: | For nutritional supplementation, also for treating dietary shortage or imbalance |
| DrugBank Pharmacology: | This compound is needed for good nerve conduction throughout the CNS (central nervous system) as it is a precursor to acetylcholine (ACh). Choline is also needed for gallbladder regulation, liver function and lecithin (a key lipid) formation. Choline also aids in fat and cholesterol metabolism and prevents excessive fat build up in the liver. Choline has been used to mitigate the effects of Parkinsonism and tardive dyskinesia. Choline deficiencies may result in excessive build-up of fat in the liver, high blood pressure, gastric ulcers, kidney and liver dysfunction and stunted growth. |
| DrugBank MoA: | Choline is a major part of the polar head group of phosphatidylcholine. Phosphatidylcholine's role in the maintenance of cell membrane integrity is vital to all of the basic biological processes: information flow, intracellular communication and bioenergetics. Inadequate choline intake would negatively affect all these processes. Choline is also a major part of another membrane phospholipid, sphingomyelin, also important for the maintenance of cell structure and function. It is noteworthy and not surprising that choline deficiency in cell culture causes apoptosis or programmed cell death. This appears to be due to abnormalities in cell membrane phosphatidylcholine content and an increase in ceramide, a precursor, as well as a metabolite, of sphingomyelin. Ceramide accumulation, which is caused by choline deficiency, appears to activate Caspase, a type of enzyme that mediates apoptosis. Betaine or trimethylglycine is derived from choline via an oxidation reaction. Betaine is one of the factors that maintains low levels of homocysteine by resynthesizing L-methionine from homocysteine. Elevated homocysteine levels are a significant risk factor for atherosclerosis, as well as other cardiovascular and neurological disorders. Acetylcholine is one of the major neurotransmitters and requires choline for its synthesis. Adequate acetylcholine levels in the brain are believed to be protective against certain types of dementia, including Alzheimer's disease. |
| Targets: | Neuronal acetylcholine receptor subunit alpha-7; Choline-phosphate cytidylyltransferase B; Acetylcholinesterase; Choline-phosphate cytidylyltransferase A; Phospholipase D2; Cholinesterase; Phospholipase D1; Phosphoethanolamine/phosphocholine phosphatase |
| Inclusion Criteria: |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S03 | anti-inflammatory | Anti-inflammatory; Anti-fibrosis; Anti-oxidative stress; Anti-inflammatory; Immunotherapy; Anti-inflammatory; Anti-apoptosis; Anti-inflammatory; Anti-inflammatory; Anti-oxidative stress; Anti-inflammatory; Anti-fibrosis; Anti-oxidative stress; Anti-inflammatory; Anti-apoptosis; Anti-inflammatory; Anti-oxidative stress; Anti-fibrosis; Enhance lipid metabolism; Anti-inflammatory; Anti-fibrosis; Enhance lipid metabolism; Anti-inflammatory; Anti-inflammatory; Immunosuppressive; Anti-inflammatory; inducing apoptosis in those cells; Anti-inflammatory; Improve insulin resistance; Enhance lipid metabolism; Regulating intestinal flora; Anti-hypertensive; Anti-oxidative stress; Anti-inflammatory; Anti-fibrosis; Improve insulin resistance; Enhance lipid metabolism; Anti-inflammatory; anti-inflammatory; anti-oxidative stress; Anti-fibrosis; Anti-inflammatory; Anti-apoptosis; Anti-hypertensive; Anti-inflammatory; Anti-fibrosis; Anti-inflammatory; Immunotherapy; Anti-hypertensive; Anti-oxidative stress; Anti-inflammatory; Anti-inflammatory; Improve insulin resistance; Anti-inflammatory; Anti-oxidative stress; Anti-apoptosis; Anti-hypertensive; Anti-inflammatory; Anti-inflammatory; Lifestyle measures; non-steroidal anti-inflammatory agents (NSAIDs); Anti-inflammatory; Anti-fibrosis; Enhance lipid metabolism; Regulating intestinal flora; Improve insulin resistance; Enhance lipid metabolism; Anti-inflammatory; Enhance lipid metabolism; Anti-oxidative stress; Anti-inflammatory; anti-inflammatory; Anti-fibrosis; Anti-inflammatory; Cell therapy; Anti-inflammatory; Anti-fibrosis; Anti-inflammatory; Anti-fibrosis; Anti-apoptosis; Immunotherapy; Anti-inflammatory; Improve insulin resistance; Anti-oxidative stress; Anti-inflammatory; Anti-fibrosis; non-steroidal anti-inflammatory drugs (NSAIDs) treatment; Anti-fibrosis; Anti-inflammatory; Anti-hypertensive; Anti-oxidative stress; Anti-inflammatory; Anti-fibrosis; Anti-apoptosis; Anti-fibrosis; Anti-inflammatory; Anti-oxidative stress; Anti-inflammatory renoprotection; anti-inflammatory effect; Enhance lipid metabolism; Anti-inflammatory; Anti-fibrosis; Anti-oxidative stress; Anti-inflammatory; Anti-oxidative stress; Anti-lipogenesis; Anti-fibrosis | NF-κB; TNF-α; NF-κB; FGF23; MAPK; caspase-3; Bcl-2; Nrf2; HO-1; p38 MAPK; JNK; FXR; TNF-α; IL-1β; IL-6; AMPK; PPAR; IL-1β; IL-6; TNF-α; ACE; Smad4; PKD1; p62; mTOR; AMPK; HIF; HIF; Smad2/3; Smad2/3; VEGFA; IL-6; MAPK; IL-1β; EGFR; TLR4; IL-6; Wnt/β-catenin; HO-1; NF-κB; TLR4; NF-κB; NF-κB; STAT3; JAK2; NOX4; NF-κB; Nrf2; SGLT2; HIF; SIRT1; JAK1; JAK2; TLR4; Smad2/3; IL-17; IL-6; PI3K; AKT; IL-6; IL-1β; TNF-α; TGF-β; EGF; IL-17; AMPK; NOX4; caspase-3; NOX4; NLRP3; caspase-1; IL-1β; ERK; JNK; p38 MAPK; NLRP3; NLRP3; NF-κB; HIF; hepcidin | MRI-1867; JD5037; 1400W; prednisolone; methotrexate; eldecalcitol; teriparatide; denosumab; streptozotocin; chloroquine; dexamethasone; 5-aminosalicylates; azathioprine; methotrexate; Glatiramer acetate; Glatiramer; paricalcitol; Oleuropein; methyl corosolate; uvaol; oleanolic acid; phenolic-rich açaí seed extract; BML-111; ML385; Recombinant thrombomodulin; obeticholic acid (OCA; 6-ethyl chenodeoxycholic acid); tropifexor; nidufexor; Tripterygium wilfordii Hook F; C4BP(x3b2; -); cyclophosphamide; methylprednisolone; cyclophosphamide; tripterygium wilfordii multiglycosides; prednisone; Astragalus; Salvia miltrorrhiza; Polygala fallax Hemsl; compound Sanqi granules; metformin; Okadaic acid; berberine; NOX5 siRNA; Tectorigenin; gentamicin; miR-218 inhibitor; methylprednisolone; prednisolone; mycophenolate mofetil; cyclosporine A; cyclophosphamide; rituximab; azathioprine; tacrolimus; propionate; Hirudin; Hsub2/subS; NO; Hsub2/subSxa0; xa0; NO; USC; prednisolone; mizoribine; angiotensin-converting enzyme inhibitors; steroids; cyclophosphamide; Korean red ginseng; Panax ginseng C.A. Mey.; streptozotocin; probiotics; Lactobacillus; Bifidobacterium; Sodium-glucose cotransporter 2 inhibitors; SGLT2 inhibitors; intravenous immunoglobulins; glucocorticoids; cyclophosphamide; azathioprine; Cyanidin-3-glucoside; Curcumin; quercetin; formononetin; calycosin; 7-O-methylisomucronulatol; quercetin; 1,25sub2/subDsub3/sub; parthenolide; insulin; Tocilizumab; Oral prednisolone; Astragaloside IV; Akebia saponin D; dioscin; streptozocin; Baicalin; tegafur/gimeracil/oteracil; furosemide; prednisolone; methylprednisolone; prednisolone; steroid; allopurinol; β-Caryophyllene; Colchicine; systemic/intra-articular corticosteroids; non-steroidal anti-inflammatory agents; IL-1 inhibitors; immunosuppressive therapy; STZ; dapagliflozin; streptozocin; Ergosterol; Streptozotocin; corticosteroids; cyclophosphamide; tofacitinib; inulin; Sodium-glucose cotransporter 2 inhibitors; curcumin; camptothecin; streptomycin; JAK inhibitors; ruxolitinib; Plantamajoside; methylprednisolone; intravenous immunoglobulin; vitamin D receptor agonists; paricalcitol; Am80; all-trans retinoic acid; Capsicum annuum L.; HPMA copolymer-based dexamethasone prodrug; PEG-based dexamethasone prodrug; glucocorticoid; cyclophosphamide; psoralen; Caffeine; glucocorticoids; Streptozotocin; paramylon; Campath; IV steroid; IV antibiotics; clindamycin; cMet agonistic antibody; short-chain fatty acids; acetate; propionate; butyrate; GPR43 agonist; Infliximab; corticosteroids; secukinumab; prednisolone; methylprednisolone; Cyclophosphamide; non-steroidal anti-inflammatory drugs; methotrexate; steroid; Dexamethasone; Tiliacora triandra extract; 5,7-dihydroxy-6-oxoheptadecanoic acid; liraglutide; enalapril; canagliflozin; isoprenaline; Liuwei Dihuang pill; streptozotocin; six novel poricoic acids from Poria cocos; poricoic acid ZM; poricoic acid ZP; secolanostane tetracyclic triterpenoids; Chuanxiong Rhizoma; Myricanone; Wallichilide; Sitosterol; Chloroquine; Amodiaquine; Streptozotocin; statins; atorvastatin; Allopurinol; febuxostat; Terminalia bellerica; saxagliptin; Adriamycin; baru almond oil; mineral oil; Epicatechin; 2,3-dihydroxybenzoic acid; 3,4-dihydroxyphenylacetic acid; 3-hydroxyphenylpropionic acid; Sauchinone; Shenkang VII recipe; porcine collagen hydrolysate; prolyl-hydroxyproline; APX-115; sodium nitrite; isoquercetin; topiroxostat; siXDH; Ginkgo biloba extract; Streptozotocin | Details |
| S14 | immunotherapy | immunosuppressants; immunosuppressive medications; immunosuppression; Immunotherapy; immunosuppressive treatments; Immunosuppressive therapy; immune-suppressive medications; Anti-inflammatory; Immunotherapy; Standard CNI-based mammalian target of rapamycin-free immunosuppression; Immunosuppression; steroid-sparing immunosuppressive protocols; Immunoadsorption; immunosuppressive therapy; Anti-inflammatory; Immunosuppressive; Immunosuppressive treatment; Immunoregulation; Immunosuppressive therapy with cyclophosphamide (CTX); Anti-inflammatory; Immunotherapy; Anti-hypertensive; Immunosuppressive treatment; Anti-hypertensive; Immunization with PTX3 to incite anti-PTX3 antibodies; immunosuppressive drugs; Immunotherapy (predizone; immunosuppressive therapies; Enhanced immunosuppressive treatment; Immunosuppressant therapy; checkpoint inhibitor (CPI) immunotherapy plus conventional chemotherapy; [Immunotherapy; targeting the mucosal immune system dysregulation underlying IgAN pathogenesis with a pH-modified formulation of budesonide; immunosuppression (primarily glucocorticoids); immunosuppressors; systemic immunosuppressant; Immunotherapy (rituximab); Intravenous immunoglobulins; Immunotherapy; Anti-inflammatory; other immunosuppressives; Immunotherapy; Genetic therapy; 'classical' immunosuppressive drugs; Immunotherapy (anti-PD1 antibodies: nivolumab or pembrolizumab); corticosteroids plus immunosuppressant; immunosuppressive agents; immunosuppressive regimen; immunosuppressive drugs; immunosuppressive therapy; Immunosuppressive intervention | angiotensin receptor; IL-2; calcineurin; CD20; FGF23; C5; PLA2R; CD20; JNK; ERK; MAPK; NLRP3; PLA2R; IL-6; B cells; IL-17; PD-1; Smad2/3; p38 MAPK; C3 | ACE-Is; ARBs; steroids; immunosuppressants; immunosuppressive medications; steroids; immunosuppression; ustekinumab; immunosuppressant; immunosuppressive treatments; corticosteroids; immune-suppressive medications; immunosuppressive medications; rituximab; RTX; IL-2; prednisolone; methotrexate; eldecalcitol; teriparatide; denosumab; calcineurin inhibitors; Sirolimus; ofatumumab; rituximab; calcineurin inhibitors; antiproliferative agents; prednisone; IVIg; SCIg; 5-aminosalicylates; azathioprine; methotrexate; Triptolide; immunosuppressants; corticosteroids; glucocorticoid; vitamin D supplementation; active vitamin D; oral phosphate; magnesium supplementation; recombinant human growth hormone; alemtuzumab; Recombinant thrombomodulin; Yi-Qi-Qing-Jie formula; prednisolone; cyclophosphamide; rituximab; steroids; mycophenolate mofetil; tacrolimus; basiliximab; antithymocyte globulins; valganciclovir; renin-angiotensin-aldosterone system blockers; Eculizumab; immunosuppressive therapy; Rituximab; steroids; cyclosporine; ofatumumab; rituximab; monoclonal antibodies; humanized anti-CD20 therapies; ofatumumab; methylprednisolone; cyclophosphamide; tripterygium wilfordii multiglycosides; prednisone; Belimumab; Benlysta; steroids; corticosteroids; immunosuppressive medication; methylprednisolone; prednisolone; mycophenolate mofetil; cyclosporine A; cyclophosphamide; rituximab; azathioprine; tacrolimus; Tris dipalladium; Tris DBA; Denosumab; cyclophosphamide; Tacrolimus; glucocorticoid; Ustekinumab; infliximab; steroid; prednisolone; mizoribine; angiotensin-converting enzyme inhibitors; steroids; cyclophosphamide; ACEI; eculizumab; steroid; steroids; immunosuppressants; PF-06730512; intravenous immunoglobulins; glucocorticoids; cyclophosphamide; azathioprine; Iguratimod; prednisone; denosumab; human recombinant PTX3; Rituximab; steroids; calcineurin inhibitors; ofatumumab; immunosuppressive drugs; prednizone; cyclosporine A; enoxaparine; Tocilizumab; Lenalidomide; anthracycline; prednisolone; prednisolone; mycophenolate mofetil; cyclophosphamide; Mycophenolic acid; MPA; enhanced immunosuppressive treatment; corticosteroids; cyclophosphamide; RAAS blockers; immunosuppression; herbal medication; herbal supplement; IV cyclophosphamide; steroids; cyclosporine; sirolimus; steroid; immunosuppressants; corticosteroids; cyclophosphamide; tofacitinib; FTY720; SEW2871; TY52156; renin angiotensin system inhibitors; corticosteroids; immunosuppressant; Checkpoint inhibitor; conventional chemotherapy; corticosteroids; anti-IL-12/23 p40 antibody; abatacept; budesonide; corticosteroid; rituximab (RTX; anti-CD20); belimumab (BLM; anti-BAFF); prednisolone; rituximab; cyclophosphamide; mycophenolate mofetil; glucocorticoids; immune checkpoint inhibitors; angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers; diuretics; corticosteroids; rituximab; immunosuppressive treatment; methylprednisolone; intravenous immunoglobulin; corticosteroids; immunosuppressors; systemic immunosuppressant; rituximab; steroids; tacrolimus; cyclosporine; cyclophosphamide; mycophenolate mofetil; Intravenous immunoglobulins; Rituximab; glucocorticoid; cyclophosphamide; immunosuppressants; certolizumab pegol; methotrexate; infliximab; rituximab; corticosteroids; cyclophosphamide; cyclophosphamide; cyclo; rituximab; belimumab; cyclophosphamide; glucocorticoids; steroid; pulse methylprednisolone; cyclophosphamide; cyclosporine; mycophenolate mofetil; rituximab; abatacept; Campath; IV steroid; IV antibiotics; clindamycin; corticosteroids; mycophenolate mofetil; other immunosuppressives; ecluzimab; Infliximab; corticosteroids; secukinumab; prednisolone; methylprednisolone; Cyclophosphamide; miR-10a-3p agomir; miR-10a-3p antagomir; REG3A low expression vector; rituximab; corticosteroids; ""'classical' immunosuppressive drugs; Janus kinase inhibitors""; antiviral medications; corticosteroid; cyclophosphamide; mycophenolate mofetil; nivolumab; pembrolizumab; renin-angiotensin-aldosterone system inhibitors; proton-pump inhibitors; corticosteroids; corticosteroids; immunosuppressant; tacrolimus; mycophenolate mofetil; tocilizumab; high dose corticosteroids; glucocorticoids; immunosuppressants; cyclosporine; rituximab; intravenous immunoglobulins; IVIg; methylprednisolone; cyclophosphamide; glucocorticoids; cyclophosphamides; steroids; immunosuppressive drugs; immunosuppressive; rituximab; nivolumab; daratumumab; bortezomib; melphalan; prednisone; thalidomide | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name | |
|---|---|---|---|---|---|---|---|
| T03 | Angiotensin-converting enzyme | ACE | INHIBITOR | Target is a single protein chain | P12821 | ACE_HUMAN | Details |
| T06 | Sulfonylurea receptor 1 | ABCC8 | Target is a single protein chain | Q09428 | ABCC8_HUMAN | Details | |
| T47 | Sialin | SLC17A5 | Target is a single protein chain | Q9NRA2 | SLC17A5_HUMAN | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I02 | 1184 | nephrotic syndrome | "A nephrosis characterized by marked increase in glomerular protein permeability resulting in marked elevation of urine protein levels, hypoalbuminemia, hyperlipidemia, and hypercoagulability." [url:https\://en.wikipedia.org/wiki/Nephrotic_syndrome, url:https\://www.niddk.nih.gov/health-information/kidney-disease/nephrotic-syndrome-adults] | Details |